Safety of Novel Oral Anticoagulants Compared With Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation

Annals of Pharmacotherapy

Volumn 49, Issue 3, 2015, Pages 278-284

  Armbruster, Heather L ^a   Lindsley, John P ^a   Moranville, Michael P ^a   Habibi, Mohammadali ^b   Khurram, Irfan M ^b   Spragg, David D ^b   Berger, Ronald D ^b   Calkins, Hugh ^b   Marine, Joseph E ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apixaban; atrial fibrillation ablation; dabigatran; novel oral anticoagulants; rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84923846587     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014563950     Document Type: Article

References (21)

1. Yamaji H,Murakami T,Hina K, et al.Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation.Clin Drug Investig. 2013;33:409-418
2. Kaseno K,Naito S,Nakamura K, et al.Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.Circ J. 2012;76:2337-2342
3. Snipelisky D,Kauffman C,Prussak, et al.A comparison of bleeding complications post-ablation between warfarin and dabigatran.J Interv Card Electrophysiol. 2012;35:29-33
4. Maddox W,Kay GN,Yamada T, et al.Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.J Cardiovasc Electrophysiol. 2013;24:861-865
5. Lakkireddy D,Reddy YM,Biase LD, et al.Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation.J Am Coll Cardiol. 2012;59:1168-1174
6. Imamura K,Yoshida A,Takei A, et al.Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.J Interv Card Electrophysiol. 2013;37:223-231
7. Eitel C,Koch J,Sommer P, et al.Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.Europace. 2013;15:1587-1593
8. Bassiouny M,Saliba W,Rickard J, et al.Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.Circ Arrhythm Electrophysiol. 2013;6:460-466
9. January CT,Wann LS,Alpert JS, et al.AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol. 2014 2014;:
10. Connolly SJ,Ezekowitz MD,Yusuf S, et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009;361:1139-1151
11. Kim J,She F,Jongnarangsin K, et al.Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.Heart Rhythm. 2013;10:483-489
12. Haines DE,Mead-Salley M,Salazar M, et al.Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.J Interv Card Electrophysiol. 2013;37:233-239
13. Kaiser DW,Streur MM,Nagarakanti R, et al.Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.J Interv Card Electrophysiol. 2013;37:241-247
14. Nin T,Sairaku A,Yoshida Y, et al.A randomized controlled trial of dabigatran verus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.Pacing Clin Electrophysiol. 2013;36:172-179
15. Piccini JP,Stevens SR,Lokhnygina Y, et al.Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.J Am Coll Cardiol. 2013;61:1998-2006
16. Dillier R,Ammar S,Reents T, et al.Safety and efficacy of continuous periprocedural rivaroxaban for patients undergoing catheter ablation procedures: a retrospective registry analysis.Heart Rhythm. 2013;10:266-267
17. Stepanyan G,Badhwar N,Lee RJ, et al.Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.J Interv Card Electrophysiol. 2014;40:33-38
18. Lakkireddy D,Reddy YM,Di Biase L, et al.Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.J Am Coll Cardiol. 2014;63:982-988
19. Schulman S,Angeras U,Berggvist D, et al.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost. 2010;8:202-204
20. Konduru SV,Cheema AA,Jones P, et al.Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.J Interv Card Electrophysiol. 2012;35:277-284
21. Kwak JJ,Pak HN,Jang JK, et al.Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation.J Cardiovasc Electrophysiol. 2010;21:620-625